ModerateVitamin K antagonist anticoagulants×Thyroid hormones
Updated · Methodology
Mechanism
Levothyroxine displaces anticoagulants from their binding to plasma proteins, so the effect of coumarins can increase (levothyroxine summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol is 98.7% bound to plasma proteins, mainly albumin, and both the originator and the generic SmPC list thyroid hormones among the drugs that can potentiate it (acenocoumarol SmPCs, AEMPS). According to the US label, levothyroxine increases the response to oral anticoagulant therapy (levothyroxine prescribing information, US Food and Drug Administration, FDA). Thyrotoxicosis can also reduce the protein binding of acenocoumarol, so strict medical supervision is needed in this condition (acenocoumarol SmPC, AEMPS).
Symptoms
The main risk is bleeding. When levothyroxine intensifies the anticoagulant effect, the risk of bleeding rises, for example bleeding in the central nervous system or gastrointestinal bleeding, especially in older people (levothyroxine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).
Management
The combination is not contraindicated but needs frequent coagulation monitoring. Check coagulation parameters regularly at the start of and during combined treatment, and reduce the anticoagulant dose if needed (levothyroxine summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US label, the anticoagulant dose may need to be lowered when hypothyroidism is corrected or the levothyroxine dose is increased. Monitor coagulation tests closely so that the dose can be adjusted in time (levothyroxine prescribing information, US Food and Drug Administration, FDA). The acenocoumarol SmPCs ask for close and frequent coagulation checks, for example twice a week. This applies both when another drug is added and when it is stopped (acenocoumarol SmPCs, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Synthroid (levothyroxine sodium) prescribing information (2017)– ; DailyMed setid 1e11ad30-1041-4520-10b0-8f9d30d30fcc
- AEMPS: Ficha técnica: Levotiroxina sódica (nº registro 77045), sección 4.5 (2026)– AEMPS, CIMA, nº registro 77045, revisión 10/2026, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Levotiroxina, Eutirox 100 microgramos (nº registro 64014), sección 4.5 (2025)– AEMPS, CIMA, nº registro 64014 (Eutirox 100 microgramos comprimidos, Merck; mismo texto de la sección 4.5 en las demás dosis de Eutirox, p. ej. nº 70042 y 64015), revisión 01/2025, sección 4.5